News


  • 14 June 2018

    Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical Announces Completion of Patient Enrollment in First of Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced completion of patient enrollment in a Phase 3 clinical trial (“SAPPHIRE”) of suprachoroidal CLS-TA used in combination with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) for the treatment of Retinal Vein Occlusion (“RVO”).

  • 31 May 2018

    Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced positive topline results from its Phase 2 clinical trial (“TYBEE”) evaluating suprachoroidal CLS-TA used with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) in patients with diabetic macular edema (“DME”) over a 6-month evaluation period.

  • 30 May 2018

    Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration

    Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2018 . In addition, the Company provided a clinical and business update. As of  March 31, 2018 , Syndax had  $113.2 million  in cash, cash equivalents and short-term investments.

  • 24 May 2018

    Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants

    Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants

    Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced the closing of its previously announced underwritten public offering of 8.5 million shares of common stock or, in lieu of shares of common stock, pre-funded warrants exercisable for shares of common stock, and accompanying common warrants to purchase an aggregate of 1.7 million shares of common stock. At closing, Evofem received net proceeds from the offering of approximately $36.4 million, after deducting offering expenses. All of the securities in the offering were sold by Evofem.

  • 22 May 2018

    Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

    Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

    Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the launch of an underwritten public offeringEvofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the pricing of an underwritten public offering of up to 8.5 million shares in aggregate of common stock or, in lieu of shares of common stock, pre-funded warrants exercisable for shares of common stock, and accompanying common warrants to purchase an aggregate of 1.7 million shares of common stock.of $40.0 million of its common stock. All of the shares in the offering are to be sold by Evofem.

  • 17 May 2018

    Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)

    Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from multiple cohorts of the ongoing Phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy. This data will be presented at the  American Society of Clinical Oncology  ( ASCO ) Annual Meeting being held  June 1-5, 2018  in  Chicago, Illinois .

  • 17 May 2018

    Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

    Celtaxsys Announces Last Patient, Last Visit in Landmark CF Phase 2b Lung Function Preservation Trial, Clinical Results Expected in July

    Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today announced the last patient, last visit in its 200-patient acebilustat Phase 2b lung function preservation trial for the treatment of cystic fibrosis (CF). This trial has been carried out with the scientific and financial support of the CF Foundation.

  • 11 May 2018

    Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation

    Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation

    At the 2018 AACR annual meeting, Epic Sciences presented data from two studies demonstrating the company's "No Cell Left Behind" detection platform's capability to analyze potential markers of response to immuno-oncology (IO) agents, such as checkpoint inhibitors, vaccines, and CAR-T therapies. The first study presented single-cell sequencing of CTCs to detect DNA damage repair deficiencies (MSI or HRD) often associated with chromosomal instability or neo-antigen formation. The second study presented detection of rare immune cell populations, in this case T-cell activation (CD4/CD8/Ki67), from the same stable archived peripheral blood samples previously prepared for CTC analysis.

  • 09 May 2018

    Clearside Biomedical Announces First Quarter 2018 Financial Results and Provides Corporate Update

    Clearside Biomedical Announces First Quarter 2018 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported financial results for the quarter ended  March 31, 2018 , and provided an update on its development programs.

  • 08 May 2018

    Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2018 . In addition, the Company provided a clinical and business update. As of  March 31, 2018 , Syndax had  $113.2 million  in cash, cash equivalents and short-term investments.